<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01954693</url>
  </required_header>
  <id_info>
    <org_study_id>SPON803-10</org_study_id>
    <secondary_id>2011-004854-25</secondary_id>
    <nct_id>NCT01954693</nct_id>
  </id_info>
  <brief_title>A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis</brief_title>
  <acronym>TRON</acronym>
  <official_title>TRON: A Randomised, Double Blind, Placebo-controlled Study of RAD001 (Everolimus) in the Treatment of Neurocognitive Problems in Tuberous Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiff University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre, two-arm, individually randomised, Phase II, double- blind,&#xD;
      placebo-controlled trial of RAD001 (Everolimus) versus placebo in the treatment of&#xD;
      neurocognitive problems in patients with tuberous sclerosis (TSC). The IMP is a licensed&#xD;
      medicine in this patient group but for a different target of effect. The current trial is a&#xD;
      proof of principle study for memory and executive function outcomes.&#xD;
&#xD;
      Following an eligibility visit, patients will be scheduled for baseline visit and&#xD;
      randomization. They will then be followed up for 6 months undergoing both safety and&#xD;
      neurocognitive assessments whilst taking either the placebo or study drug.&#xD;
&#xD;
      48 patients aged 16 to 60 years with tuberous sclerosis (TSC) who have IQ &gt; 60 and a&#xD;
      significant deficit in one or more primary outcome measures will be randomly allocated in a&#xD;
      ratio of 2:1 to either RAD001 (Everolimus) or Placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">August 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>List Learning test (from the BIRT Memory and Information Processing Battery)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complex Figure test (from the BIRT Memory and Information Processing Battery)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CANTAB - Stockings of Cambridge (SOC)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CANTAB - Spatial Working Memory (SWM)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Telephone search dual task (from the Test of Everyday Attention)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CANTAB - Rapid Visual Information Processing Battery (RVIP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CANTAB - Spatial Span (SSP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CANTAB - Attentional Set-shifting (IDED)</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Fluency /Controlled Oral Word Association Test (COWAT)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation task</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Checklist 90R (SCL-90R)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Epilepsy (QOLIE)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liverpool Seizure Severity Scale (LSSS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland Adaptive Behavior Scales-II (VABS-II) (survey form)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Responsiveness Scale - Adult version (SRS-A)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social communication questionnaire (SCQ)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Adult Reading Test (NART)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Wechsler Abbreviated Scale of Intelligence (WASI) (4 subtests)</measure>
    <time_frame>Eligibility visit</time_frame>
    <description>Eligibility visit screening measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Edinburgh Handedness Test</measure>
    <time_frame>Eligibility visit</time_frame>
    <description>Eligibility visit screening measures</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Tuberous Sclerosis</condition>
  <arm_group>
    <arm_group_label>Everolimus (RAD001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x2.5mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2x2.5mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus (RAD001)</intervention_name>
    <description>5mg daily administered for 6 months as two oral 2.5 mg tablets once daily</description>
    <arm_group_label>Everolimus (RAD001)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Definite TSC by current clinical criteria (28);&#xD;
&#xD;
          2. Male or female aged 16 to 60 yrs;&#xD;
&#xD;
          3. IQ over 60 by Wechsler Abbreviated Scales of Intelligence (WASI) and able to&#xD;
             participate in direct neuropsychological tests;&#xD;
&#xD;
          4. A score falling on, or below, the 5th percentile (approximately equivalent to -1.5 SD)&#xD;
             in one or more of the primary outcome measures:&#xD;
&#xD;
          5. Calculated GFR &gt; 60ml/min/1.73m2 except in case of renal impairment associated with&#xD;
             TSC complicating kidneys, where a calculated GFR should be â‰¥30ml/min/1.73m2;&#xD;
&#xD;
          6. INR 1.5 or less (anticoagulation permitted if target INR on stable dose of warfarin or&#xD;
             LMW heparin for &gt; 2 weeks at time of randomisation) ;&#xD;
&#xD;
          7. Adequate liver function as shown by: serum bilirubin less than or equal to 1.5 x ULN,&#xD;
             ALT and AST less than or equal to 2.5 x ULN;&#xD;
&#xD;
          8. If sexually active - negative pregnancy test in females at the time of informed&#xD;
             consent, contraception for males and pre-menopausal females on study);&#xD;
&#xD;
          9. Seizure free or stable seizures as defined by no change in type of AEDs in 6 months&#xD;
             prior to full recruitment and randomization at baseline. Doses of drugs may have been&#xD;
             changed in the 6 months prior to recruitment;&#xD;
&#xD;
         10. Hepatitis B surface antigen negative, Hepatitis C antibody negative.&#xD;
&#xD;
         11. All patients must be able to communicate well with the investigator, to understand and&#xD;
             comply with the requirements of the study, understand and sign the written informed&#xD;
             consent;&#xD;
&#xD;
         12. Female patients of childbearing potential must be prepared to use two acceptable&#xD;
             methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel&#xD;
             plus condom, diaphragm plus condom, etc.), from the time of screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with an mTOR inhibitor;&#xD;
&#xD;
          2. Investigational agent &lt;30 days prior to randomisation;&#xD;
&#xD;
          3. Surgery in last 2 months;&#xD;
&#xD;
          4. Previous brain neurosurgery;&#xD;
&#xD;
          5. Significant haematological abnormality i.e. haemoglobin &lt; 8g/dL, platelets&#xD;
             &lt;80,000/mm3, absolute neutrophil count &lt; 1000/mm3);&#xD;
&#xD;
          6. Urine protein/creatinine &gt;0.02g/mmol except in case of renal impairment associated&#xD;
             with TSC complication of kidneys, where urine protein/creatinine ratio should be&#xD;
             &gt;0.1g/mmol for exclusion;&#xD;
&#xD;
          7. Serum creatinine &gt; 1.5 x ULN except in case of renal impairment associated with TSC&#xD;
             complication of kidneys, where serum creatinine should be &gt;300Âµmol/L for exclusion;&#xD;
&#xD;
          8. Uncontrolled hyperlipidaemia (fasting cholesterol &gt; 300mg/dL or &gt;7.75 mmol/L and&#xD;
             fasting triglycerides &gt;2.5 x ULN, or diabetes with fasting serum glucose &gt; 1.5 x ULN;&#xD;
&#xD;
          9. History of myocardial infarction, angina or stroke related to atherosclerosis, or any&#xD;
             other significant cardiac disease, HIV seropositivity, organ transplant, malignancy&#xD;
             other than squamous or basal cell skin cancer;&#xD;
&#xD;
         10. lymphangioleiomyomatosis with FEV1 &lt;70% of predicted, or any other restrictive&#xD;
             pulmonary disease;&#xD;
&#xD;
         11. Bleeding diathesis or on oral anti-vitamin K medication other than low dose warfarin;&#xD;
&#xD;
         12. Pregnancy/lactation;&#xD;
&#xD;
         13. Live vaccine required during trial;&#xD;
&#xD;
         14. Use of strong inhibitor of CYP3AE;&#xD;
&#xD;
         15. Use of strong inducer of CYP3AE except for anti epileptic drugs;&#xD;
&#xD;
         16. Intercurrent infection at time of randomisation;&#xD;
&#xD;
         17. Inability to complete study materials (outcome measures) in English;&#xD;
&#xD;
         18. History of significant trauma-related cognitive deficit;&#xD;
&#xD;
         19. Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of Everolimus (e.g. pancreatic insufficiency);&#xD;
&#xD;
         20. Known sensitivity to Everolimus or other Rapamycin analogues or to its excipients;&#xD;
&#xD;
         21. Inability to attend scheduled visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Sampson, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiff University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4YS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2013</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiff University</investigator_affiliation>
    <investigator_full_name>Julian Sampson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Tuberous Sclerosis</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Neurocognitive functioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

